Please use this identifier to cite or link to this item: http://hdl.handle.net/10321/1608
Title: Designing new kinase inhibitor derivatives as therapeutics against common complex diseases : structural basis of microtubule affinity-regulating kinase 4 (MARK4) inhibition
Authors: Naz, Farha 
Shahbaaz, Mohd 
Bisetty, Krishna 
Islam, Asimul 
Ahmad, Faizan 
Hassan, Md. Imtaiyaz 
Issue Date: 2015
Publisher: Mary Ann Liebert, Inc.
Source: Naz, F. et al. 2015. Designing new kinase inhibitor derivatives as therapeutics against common complex diseases : structural basis of microtubule affinity-regulating kinase 4 (MARK4) inhibition. OMICS: A Journal of Integrative Biology, 19(11): 700-711.
Abstract: Drug development for common complex diseases is in need of new molecular entities and actionable drug targets. MAP/microtubule affinity-regulating kinase 4 (MARK4) is associated with numerous diseases such as neurodegenerative disorders, obesity, cancer, and type 2 diabetes. Understanding the structural basis of ligands’ (inhibitors) and substrates’ binding to MARK4 is crucial to design new kinase inhibitors for therapeutic pur-poses. This study reports new observations on docking three well-known kinase inhibitors in the kinase domain of MARK4 variants and the calculated binding affinity. These variants of MARK4 are named as MARK4-F1 (59 N-terminal residues along with kinase domain) and MARK4-F2 (kinase domain of MARK4). We addi-tionally performed molecular dynamics (MD) simulation and fluorescence binding studies to calculate the actual binding affinity of kinase inhibitors, BX-912, BX-795, and OTSSP167 (hydrochloride) for the MARK4. Docking analyses revealed that ligands bind in the large hydrophobic cavity of the kinase domain of MARK4 through several hydrophobic and hydrogen-bonded interactions. Simulations suggested that OTSSP167 (hy-drochloride) is forming a stable complex, and hence the best inhibitor of MARK4. Intrinsic fluorescence of MARK4 was significantly quenched by addition of ligands, indicating their potential binding to MARK4. A lower KD value of MARK4 with OTSSP167 (hydrochloride) suggested that it is a better interacting partner than BX-912 and BX-795. These data form a basis for designing novel and potent OTSSP167 (hydrochloride) derivatives as therapeutic candidates against common complex diseases. The inhibitors designed as such might possibly suppress the growth of tumor-forming cells and be potentially applied for treatment of a wide range of human cancers as well.
URI: http://hdl.handle.net/10321/1608
ISSN: 1536-2310
Appears in Collections:Research Publications (Applied Sciences)

Files in This Item:
File Description SizeFormat 
Naz_OMICS-JIB_Vol19No11_2015.pdf505.65 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

95
checked on Oct 20, 2018

Download(s)

118
checked on Oct 20, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.